Abstract
The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public‐private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale‐up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence‐enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine.
Highlights
Understanding the clinical landscape and manufacturing challenges in cell-based therapies[1] is a critical first step to bringing these advanced therapies to the patient
These perspective reports developed by Regenerative Medicine Manufacturing Society (RMMS) working groups and the leadership team will be published annually in Stem Cell Translational Medicine, the official journal for RMMS
We are seeking new global collaborations[37] where we envision being able to attract additional talents that will assist our mission in advancing regenerative medicine through developing manufacturing solutions and advancements
Summary
Understanding the clinical landscape and manufacturing challenges in cell-based therapies[1] is a critical first step to bringing these advanced therapies to the patient. Standards could be developed including documentary standards, reference materials, or reference data These working groups will help evaluate the current landscape of work already done in both regenerative medicine and related fields such as cell therapy manufacturing, identify gaps, and propose solution spaces for the field to focus on. The society will work to develop education and training programs to build competencies in all aspects of regenerative medicine (from tissue/cell harvest, transport, cell/tissue manufacturing, packaging, quality, regulatory, distribution, infusion/implant). These competencies can build the workforce in regenerative medicine that industry and academic translational programs desperately need to improve patient outcomes in hitherto unimaginable ways
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
